Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes
Your plan should specify when to move up, when to hold, and what to do after a missed dose
Pharma companies funding clinical trials and the researchers who work on them are an inevitable part of drug research and development
For the 670 randomized patients, at study entry (Week 0) mean body weight was 107.3 kg and mean BMI was 38.4 kg/m2, and at randomization (Week 36, after the open-label ZEPBOUND lead-in period) mean body weight was 85.2 kg and mean BMI was 30.5 kg/m2
In 2023 , the FDA approved Zepbound for weight loss and chronic weight management in people with obesity or overweight and a weight-related health condition (e.g., high blood pressure, sleep apnea)
Values reflect findings as reported in the published research literature and are provided for research context only
